Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs.

Zhang M, Haughey M, Wang NY, Blease K, Kapoun AM, Couto S, Belka I, Hoey T, Groza M, Hartke J, Bennett B, Cain J, Gurney A, Benish B, Castiglioni P, Drew C, Lachowicz J, Carayannopoulos L, Nathan SD, Distler J, Brenner DA, Hariharan K, Cho H, Xie W.

PLoS One. 2020 Mar 11;15(3):e0229445. doi: 10.1371/journal.pone.0229445. eCollection 2020.

2.

Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry.

Shlobin OA, Kouranos V, Barnett SD, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Lower EE, Engel PJ, Wort J, Price L, Wells AU, Nathan SD, Baughman RP.

Eur Respir J. 2020 Mar 26. pii: 1901747. doi: 10.1183/13993003.01747-2019. [Epub ahead of print]

PMID:
32139456
3.

A Randomized, double-blind, placebo-controlled study to assess the safety and efficacy of pulsed, inhaled nitric oxide (iNO) at a dose of 30 mcg/kg-IBW/hr (iNO 30) in subjects at risk of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF) receiving Oxygen Therapy.

Nathan SD, Flaherty KR, Glassberg MK, Raghu G, Swigris J, Alvarez R, Ettinger N, Loyd J, Fernandes P, Gillies H, Kim B, Shah P, Lancaster L.

Chest. 2020 Feb 21. pii: S0012-3692(20)30327-5. doi: 10.1016/j.chest.2020.02.016. [Epub ahead of print]

PMID:
32092321
4.

FVC variability in patients with IPF and role of 6-min walk test to predict further change.

Nathan SD, Yang M, Morgenthien EA, Stauffer JL.

Eur Respir J. 2020 Feb 6. pii: 1902151. doi: 10.1183/13993003.02151-2019. [Epub ahead of print] No abstract available.

PMID:
32029447
5.

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Glassberg MK, Nathan SD, Lin CY, Morgenthien EA, Stauffer JL, Chou W, Noble PW.

Adv Ther. 2019 Oct;36(10):2927-2929. doi: 10.1007/s12325-019-01082-6.

6.

Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.

Aryal S, Katugaha SB, Cochrane A, Brown AW, Nathan SD, Shlobin OA, Ahmad K, Marinak L, Chun J, Fregoso M, Desai S, King C.

Transpl Infect Dis. 2019 Dec;21(6):e13166. doi: 10.1111/tid.13166. Epub 2019 Sep 18.

PMID:
31487755
7.

Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. Echoes of the Past, Lessons for the Future.

Nathan SD.

Am J Respir Crit Care Med. 2019 Dec 15;200(12):1459-1461. doi: 10.1164/rccm.201908-1510ED. No abstract available.

8.

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.

Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU.

Lancet Respir Med. 2019 Sep;7(9):780-790. doi: 10.1016/S2213-2600(19)30250-4. Epub 2019 Aug 12.

PMID:
31416769
9.

Contemporary optimized practice in the management of pulmonary sarcoidosis.

Aryal S, Nathan SD.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619868935. doi: 10.1177/1753466619868935. Review.

10.

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Glassberg MK, Nathan SD, Lin CY, Morgenthien EA, Stauffer JL, Chou W, Noble PW.

Adv Ther. 2019 Oct;36(10):2910-2926. doi: 10.1007/s12325-019-01052-y. Epub 2019 Aug 10. Erratum in: Adv Ther. 2019 Sep 9;:.

11.

Pulmonary hypertension due to interstitial lung disease.

King CS, Nathan SD.

Curr Opin Pulm Med. 2019 Sep;25(5):459-467. doi: 10.1097/MCP.0000000000000599.

PMID:
31365380
12.

Multimodal noninvasive prediction of pulmonary hypertension in IPF.

Sonti R, Gersten RA, Barnett S, Brown AW, Nathan SD.

Clin Respir J. 2019 Sep;13(9):567-573. doi: 10.1111/crj.13059. Epub 2019 Jul 30.

PMID:
31301257
13.

Pulmonary hypertension due to interstitial lung disease.

King CS, Nathan SD.

Curr Opin Pulm Med. 2019 Jun 18. doi: 10.1097/MCP.0000000000000599. [Epub ahead of print]

PMID:
31219836
14.

Curcumin induced oxidative stress attenuation by N-acetylcysteine co-treatment: a fibroblast and epithelial cell in-vitro study in idiopathic pulmonary fibrosis.

Rodriguez LR, Bui SN, Beuschel RT, Ellis E, Liberti EM, Chhina MK, Cannon B, Lemma M, Nathan SD, Grant GM.

Mol Med. 2019 Jun 13;25(1):27. doi: 10.1186/s10020-019-0096-z.

15.

Connective tissue disease-associated interstitial lung disease and outcomes after hospitalization: A cohort study.

Ratwani AP, Ahmad KI, Barnett SD, Nathan SD, Brown AW.

Respir Med. 2019 Jul - Aug;154:1-5. doi: 10.1016/j.rmed.2019.05.020. Epub 2019 Jun 4.

PMID:
31176795
16.

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.

Nathan SD, Costabel U, Albera C, Behr J, Wuyts WA, Kirchgaessler KU, Stauffer JL, Morgenthien E, Chou W, Limb SL, Noble PW.

Respir Med. 2019 Jul;153:44-51. doi: 10.1016/j.rmed.2019.04.016. Epub 2019 Apr 24.

17.

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

18.

Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study.

Raghu G, Flaherty KR, Lederer DJ, Lynch DA, Colby TV, Myers JL, Groshong SD, Larsen BT, Chung JH, Steele MP, Benzaquen S, Calero K, Case AH, Criner GJ, Nathan SD, Rai NS, Ramaswamy M, Hagmeyer L, Davis JR, Gauhar UA, Pankratz DG, Choi Y, Huang J, Walsh PS, Neville H, Lofaro LR, Barth NM, Kennedy GC, Brown KK, Martinez FJ.

Lancet Respir Med. 2019 Jun;7(6):487-496. doi: 10.1016/S2213-2600(19)30059-1. Epub 2019 Apr 1.

PMID:
30948346
19.

Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation.

Agbor-Enoh S, Wang Y, Tunc I, Jang MK, Davis A, De Vlaminck I, Luikart H, Shah PD, Timofte I, Brown AW, Marishta A, Bhatti K, Gorham S, Fideli U, Wylie J, Grimm D, Goodwin N, Yang Y, Patel K, Zhu J, Iacono A, Orens JB, Nathan SD, Marboe C, Berry GJ, Quake SR, Khush K, Valantine HA.

EBioMedicine. 2019 Feb;40:541-553. doi: 10.1016/j.ebiom.2018.12.029. Epub 2019 Jan 26.

20.

Left Ventricular Function Before and After Aerobic Exercise Training in Women With Pulmonary Arterial Hypertension.

Woolstenhulme JG, Guccione AA, Herrick JE, Collins JP, Nathan SD, Chan L, Keyser RE.

J Cardiopulm Rehabil Prev. 2019 Mar;39(2):118-126. doi: 10.1097/HCR.0000000000000397.

21.

Pulmonary hypertension in chronic lung disease and hypoxia.

Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801914. doi: 10.1183/13993003.01914-2018. Print 2019 Jan.

22.

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.

Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR; UK NIHR BioResource Rare Diseases Consortium; UK PAH Cohort Study Consortium; US PAH Biobank Consortium.

Lancet Respir Med. 2019 Mar;7(3):227-238. doi: 10.1016/S2213-2600(18)30409-0. Epub 2018 Dec 5.

23.

Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.

Nathan SD, Costabel U, Glaspole I, Glassberg MK, Lancaster LH, Lederer DJ, Pereira CA, Trzaskoma B, Morgenthien EA, Limb SL, Wells AU.

Chest. 2019 Apr;155(4):712-719. doi: 10.1016/j.chest.2018.11.008. Epub 2018 Nov 22.

24.

Novel management strategies for idiopathic pulmonary fibrosis.

Ahmad K, Nathan SD.

Expert Rev Respir Med. 2018 Oct;12(10):831-842. doi: 10.1080/17476348.2018.1513332. Epub 2018 Aug 30. Review.

PMID:
30136607
25.

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials.

Nathan SD, Lancaster LH, Albera C, Glassberg MK, Swigris JJ, Gilberg F, Kirchgaessler KU, Limb SL, Petzinger U, Noble PW.

BMJ Open Respir Res. 2018 Aug 2;5(1):e000323. doi: 10.1136/bmjresp-2018-000323. eCollection 2018.

26.

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.

Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, Axmann J, Nathan SD.

Respiration. 2018;96(6):514-524. doi: 10.1159/000490667. Epub 2018 Aug 16.

27.

Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease.

Jose A, King CS, Shlobin OA, Brown AW, Wang C, Nathan SD.

Eur Respir J. 2018 Sep 27;52(3). pii: 1801015. doi: 10.1183/13993003.01015-2018. Print 2018 Sep. No abstract available.

28.

Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.

Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Kouranos V, O'Hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Nathan SD.

Respir Med. 2018 Jun;139:72-78. doi: 10.1016/j.rmed.2018.04.015. Epub 2018 May 5.

PMID:
29858005
29.

Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia.

King CS, Brown AW, Shlobin OA, Weir N, Libre M, Franco-Palacios D, Ahmad S, Nathan SD.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800545. doi: 10.1183/13993003.00545-2018. Print 2018 Jul. No abstract available.

30.

Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.

Behr J, Nathan SD, Harari S, Wuyts W, Kirchgaessler KU, Bengus M, Gilberg F, Wells AU.

Respir Med. 2018 May;138:13-20. doi: 10.1016/j.rmed.2018.03.019. Epub 2018 Mar 16.

31.

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.

Aryal S, Nathan SD.

Expert Opin Emerg Drugs. 2018 Jun;23(2):159-172. doi: 10.1080/14728214.2018.1471465. Epub 2018 May 8. Review.

PMID:
29718783
32.

Single vs. bilateral lung transplantation: when and why.

Aryal S, Nathan SD.

Curr Opin Organ Transplant. 2018 Jun;23(3):316-323. doi: 10.1097/MOT.0000000000000527. Review.

PMID:
29629995
33.

Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation.

El-Chemaly S, O'Brien KJ, Nathan SD, Weinhouse GL, Goldberg HJ, Connors JM, Cui Y, Astor TL, Camp PC Jr, Rosas IO, Lemma M, Speransky V, Merideth MA, Gahl WA, Gochuico BR.

PLoS One. 2018 Mar 16;13(3):e0194193. doi: 10.1371/journal.pone.0194193. eCollection 2018.

34.

A 24-Year-Old Woman With Precipitous Respiratory Failure After Lung Transplantation.

Warren WA, Franco-Palacios D, King CS, Shlobin OA, Nathan SD, Katugaha SB, Mani H, Brown AW.

Chest. 2018 Mar;153(3):e53-e56. doi: 10.1016/j.chest.2017.08.020.

PMID:
29519311
35.

Dental Personnel Treated for Idiopathic Pulmonary Fibrosis at a Tertiary Care Center - Virginia, 2000-2015.

Nett RJ, Cummings KJ, Cannon B, Cox-Ganser J, Nathan SD.

MMWR Morb Mortal Wkly Rep. 2018 Mar 9;67(9):270-273. doi: 10.15585/mmwr.mm6709a2.

36.

Global Gene Expression Analysis in an in vitro Fibroblast Model of Idiopathic Pulmonary Fibrosis Reveals Potential Role for CXCL14/CXCR4.

Rodriguez LR, Emblom-Callahan M, Chhina M, Bui S, Aljeburry B, Tran LH, Novak R, Lemma M, Nathan SD, Grant GM.

Sci Rep. 2018 Mar 5;8(1):3983. doi: 10.1038/s41598-018-21889-7.

37.

RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs.

Yeo J, Morales DA, Chen T, Crawford EL, Zhang X, Blomquist TM, Levin AM, Massion PP, Arenberg DA, Midthun DE, Mazzone PJ, Nathan SD, Wainz RJ, Nana-Sinkam P, Willey PFS, Arend TJ, Padda K, Qiu S, Federov A, Hernandez DR, Hammersley JR, Yoon Y, Safi F, Khuder SA, Willey JC.

BMC Pulm Med. 2018 Mar 5;18(1):42. doi: 10.1186/s12890-018-0603-y.

38.

Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis.

Agbor-Enoh S, Jackson AM, Tunc I, Berry GJ, Cochrane A, Grimm D, Davis A, Shah P, Brown AW, Wang Y, Timofte I, Shah P, Gorham S, Wylie J, Goodwin N, Jang MK, Marishta A, Bhatti K, Fideli U, Yang Y, Luikart H, Cao Z, Pirooznia M, Zhu J, Marboe C, Iacono A, Nathan SD, Orens J, Valantine HA, Khush K.

J Heart Lung Transplant. 2018 Jul;37(7):925-932. doi: 10.1016/j.healun.2018.01.1305. Epub 2018 Jan 31.

PMID:
29500138
39.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U.

Eur Respir Rev. 2017 Dec 6;26(146). pii: 170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Review.

40.

Evaluating new treatment options.

Nathan SD.

Am J Manag Care. 2017 Jul;23(11 Suppl):S183-S190.

41.

The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis.

Brown AW, Nathan SD.

Ann Am Thorac Soc. 2018 Jan;15(1):3-10. doi: 10.1513/AnnalsATS.201703-244FR. Review.

PMID:
28933948
42.

Pitfalls in developing new compounds for idiopathic pulmonary fibrosis.

Nathan SD, Martinez FJ.

Curr Opin Pulm Med. 2017 Sep;23(5):426-431. doi: 10.1097/MCP.0000000000000407. Review.

PMID:
28771451
43.

A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma.

Kaler M, Barochia AV, Weir NA, Cuento RA, Stylianou M, Roth MJ, Filie AC, Vaughey EC, Nathan SD, Levine SJ.

J Allergy Clin Immunol. 2017 Dec;140(6):1716-1718. doi: 10.1016/j.jaci.2017.05.033. Epub 2017 Jun 15. No abstract available.

44.

Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension.

Jose A, King CS, Shlobin OA, Kiernan JM, Cossa NA, Brown AW, Nathan SD.

Chest. 2017 Nov;152(5):980-989. doi: 10.1016/j.chest.2017.05.008. Epub 2017 May 17.

PMID:
28527879
45.

Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670. doi: 10.1164/rccm.201701-0150WS.

46.

Early postoperative management after lung transplantation: Results of an international survey.

King CS, Valentine V, Cattamanchi A, Franco-Palacios D, Shlobin OA, Brown AW, Singh R, Bogar L, Nathan SD.

Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12985. Epub 2017 May 29.

PMID:
28425132
47.

Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension.

Maher TM, Dejonckheere F, Nathan SD.

J Manag Care Spec Pharm. 2017 Mar;23(3-b Suppl):S3-S4. doi: 10.18553/jmcp.2017.23.3-b.s3. Review.

48.

Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis.

Fisher M, Nathan SD, Hill C, Marshall J, Dejonckheere F, Thuresson PO, Maher TM.

J Manag Care Spec Pharm. 2017 Mar;23(3-b Suppl):S17-S24. doi: 10.18553/jmcp.2017.23.3-b.s17.

49.

The Diagnosis and Management of Airway Complications Following Lung Transplantation.

Mahajan AK, Folch E, Khandhar SJ, Channick CL, Santacruz JF, Mehta AC, Nathan SD.

Chest. 2017 Sep;152(3):627-638. doi: 10.1016/j.chest.2017.02.021. Epub 2017 Mar 6. Review.

PMID:
28274791
50.

sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension.

Benza R, Mathai S, Nathan SD.

Respir Med. 2017 Jan;122 Suppl 1:S28-S34. doi: 10.1016/j.rmed.2016.11.010. Epub 2016 Nov 14. Review.

Supplemental Content

Loading ...
Support Center